Results 261 to 270 of about 15,351,209 (418)

Cancer nanomedicine: progress, challenges and opportunities

open access: yesNature Reviews. Cancer, 2016
Jinjun Shi   +3 more
semanticscholar   +1 more source

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression

open access: yesMolecular Oncology, EarlyView.
Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park   +6 more
wiley   +1 more source

Walking Speed and Risk of Cancer in Two Prospective Cohort Studies. [PDF]

open access: yesJ Cachexia Sarcopenia Muscle
Mak JKL   +4 more
europepmc   +1 more source

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

open access: yesInternational Journal of Cancer, 2010
J. Ferlay   +5 more
semanticscholar   +1 more source

Stochastic variation in the FOXM1 transcription program mediates replication stress tolerance

open access: yesMolecular Oncology, EarlyView.
Cellular heterogeneity is a major cause of drug resistance in cancer. Segeren et al. used single‐cell transcriptomics to investigate gene expression events that correlate with sensitivity to the DNA‐damaging drugs gemcitabine and prexasertib. They show that dampened expression of transcription factor FOXM1 and its target genes protected cells against ...
Hendrika A. Segeren   +4 more
wiley   +1 more source

Using Integrative Therapies to Improve Patient-Reported Outcomes in Breast Cancer Survivors: A Living Evidence-Based Clinical Practice Guideline. [PDF]

open access: yesJ Evid Based Med
Lu T   +21 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy